John GF Cleland

May 25, 2023 | cfrjournal.com | Martha Gulati |John GF Cleland |Subodh Verma |David E. Lanfear

Video HFA 23: Diagnosis in Heart Failure in Women Published: Views: 17 Likes: 0 ESC-HFA 2023 – Prof John Cleland (University of Glasgow, Glasgow, UK) discusses the findings from a study that looked at the diagnostic of heart failure in a cohort of 1.1 million people using the NHS EMR database. Finding presented at Heart Failure 2023, showed that more people treated with LD than receive diagnosis of heart failure, this disparity was greater in women compared to men.

May 25, 2023 | cfrjournal.com | Paul Kalra |John GF Cleland |Stephen Greene

"Hello. My name is Paul Kalra. I’m consultant cardiologist and heart failure specialist at Portsmouth Hospital's University NH Trust in the United Kingdom. And I was chief investigator for IRONMAN, which was atrial that was funded by the British Heart Foundation. Please briefly outline the IRONMAN Trial. So, IRONMAN was a randomized trial of intravenous ferric derisomaltose and usual care versus usual care alone in patients with heart failure, a reduced ejection fraction and an iron deficiency.

May 24, 2023 | cfrjournal.com | Paul Kalra |John GF Cleland |Stephen Greene

ESC-HFA 23 - Prof John Cleland (University of Glasgow, UK) joins us onsite to discuss the IRONMAN trial (NCT02642562). IRONMAN was a randomised, open-label multicenter trial, which aimed to assess the effectiveness of intravenous iron in patients with heart failure and iron deficiency as compared to standard care. It demonstrated that the administration of IV FDI was associated with lower rates of recurrent heart failure hospitalisations and cardiovascular death.

May 23, 2023 | cfrjournal.com | John GF Cleland |Harriette Van Spall |Scott Solomon |Paul Kalra

Video HFA 23: DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction Published: Views: 38 Likes: 1 ESC-HFA 2023 - Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, US) joins us onsite to discuss a study that looked into Kansas City Cardiomyopathy Questionnaire (KCCQ) scores in patients with varying ejection fractions, that were enrolled in the DELIVER and DAPA-HF trials.